Arvind Sood | VP, IR |
Dr. David Reese | Head of R&D |
Dr. Greg Friberg | VP, Global Development and Therapeutic Area Head for Oncology |
Dr. Max Topp | Head of Hematology at University Hospital Wnrzburg, Germany |
Geoff Porges | Leerink |
Ying Huang | Bank of America-Merrill Lynch |
Ronny Gal | Bernstein |
Mike Yee | Jefferies |
Kennen Mackay | RBC Capital |
Terence Flynn | Goldman |
Alethia Young | Cantor |
Yaron Werber | Cowen and Company |
Matt Phipps | William Blair |
Evan Seigerman | Credit Suisse |
Chris Richard | Tekla |
Brian Skorney | Baird |
Carter Gould | UBS |
Okay, so we'll go on and get started. Good evening, everybody. I'd like to welcome you to our event this evening. And I know there are a lot of other events ongoing at the same time, but I think you made the right choice.
So it's a great opportunity for us to, of course, talk about AMG 420 and other data that has been represented in the scientific sessions here at ASH, but it's also an opportunity for us to talk about the broader oncology portfolio.